SK Plasma supplies 39 billion worth of blood products

to Singapore

About 120,000 liters of blood products were processed and exported over 6 years

SK Plasma announced on the 28th that it will begin full-fledged production this month after receiving product approval for blood products (albumin and immunoglobulin) from the Singapore Health Authority (HSA).

 

The company will independently supply a total of 30 million dollars (39 billion won) worth of blood derivatives over the next six years, starting with the initial export in the fourth quarter.

 

When the Singapore health authorities send plasma secured through their own blood source to SK Plasma, SK Plasma produces finished blood products such as albumin using the plasma as raw material at the Andong plant and sends it to Singapore.

 

In 2022, Singapore's health authorities designated SK Plasma's blood product as a priority review target.

 

As a result, the approval review process, which normally takes 18 months, was shortened by 5 months.

 

Blood products are medicines that use blood as raw material, and are manufactured in the form of medicines such as albumin and immunoglobulin by fractionating and refining blood components.

 

It is used as an essential treatment in various fields such as shock caused by excessive bleeding, congenital immunodeficiency disease, and hemophilia.

 

In a national disaster situation, blood products such as albumin and immunoglobulin are widely needed, so they are designated and managed as essential national medicines.

 

The Singapore government is supplying blood products to its citizens in the form of a national tender.

 

In the 2021 blood product bidding by the health authorities, SK Plasma was selected as the first Asian country to consign production of the entire volume.

 

SK Plasma plans to process and export approximately 20,000 liters of blood products annually to Singapore.

 

The Singapore plasma, which has been stocked since this year, will be put into production soon.

 

In addition, it plans to accelerate its global business by cooperating with foreign countries to introduce local raw material plasma and promote consignment production.

 

Kim Seung-Joo, CEO of SK Plasma, said, "This toll processing of blood products is an example of SK Plasma's technological prowess being recognized as the first exclusive toll processing export of a country at the EU GMP level." We plan to continue to expand," he said.

 

SK Plasma is promoting the construction of a blood derivatives plant in Indonesia.

 

In March, a blood product plant near Jakarta, Indonesia, which can process 1 million liters of plasma raw material per year, is under construction with the goal of completion in 2025.